Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
- Advanced environmental performance through renewable energy transition and enhanced carbon transparency
- Strengthened sustainability management and supply chain engagement across the healthcare value chain
Incheon, S. Korea, June 30, 2026 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), published its annual environmental, social, and governance (ESG) report, highlighting continued progress in sustainable operations, responsible business practices, and governance.
The report reflects Samsung Biologics' commitment to integrating sustainability into its business and operations while meeting the evolving expectations of clients, stakeholders, and the broader biopharmaceutical industry. To further enhance the transparency and accessibility of its disclosures, the company continued to advance its reporting framework in alignment with the European Sustainability Reporting Standards (ESRS) and published a dedicated ESG Factbook that provides a consolidated view of key sustainability metrics and performance data.
During the reporting period, Samsung Biologics accelerated its environmental performance through renewable energy transition, greenhouse gas emissions management, and enhanced carbon reporting. The company's renewable energy transition rate under its RE100 roadmap increased to 39.8%, while Scope 3 greenhouse gas emissions reporting coverage expanded from 56.3% to 63.7%, providing greater visibility across its value chain. Samsung Biologics also achieved third-party validation of its product carbon footprint (PCF) methodology, supporting clearer communication in sustainability reporting. In addition, the company received an 'A' rating in Water Security from the Carbon Disclosure Project (CDP), reflecting its ongoing focus on environmental stewardship and resource management.
On the social front, Samsung Biologics focused on talent cultivation and broader value chain engagement. The company operated career development programs in partnership with leading educational institutions to help cultivate future biotechnology talent, while also advancing professional growth and leadership opportunities for women in its workforce. The company also expanded supplier sustainability assessments and engagement programs, with participation reaching 57.3%, helping strengthen responsible sourcing practices and supply chain resilience.
The company further enhanced its governance framework by strengthening ethical risk management and advancing oversight practices. Through a more diversified evaluation approach, Samsung Biologics reinforced the objectivity, credibility, and independence of governance oversight, supporting effective decision-making and long-term value creation.
Beyond its own operations, Samsung Biologics engaged with stakeholders across the healthcare ecosystem to support industry-wide sustainability goals. As a champion of the Sustainable Markets Initiative (SMI) Health Systems Task Force, the company actively participated in collaborative efforts aimed at advancing more sustainable healthcare value chains and supporting the industry's transition toward a lower-carbon future.
“Sustainability is an important part of how we operate and create long-term value,” said John Rim, President and CEO of Samsung Biologics. “Through steady investments in environmental performance, robust governance, and industry-wide collaboration, we aim to contribute to the long-term resilience of the industry and the patients it serves.”
The full report is available here.
- Advanced environmental performance through renewable energy transition and enhanced carbon transparency
- Strengthened sustainability management and supply chain engagement across the healthcare value chain
Incheon, S. Korea, June 30, 2026 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), published its annual environmental, social, and governance (ESG) report, highlighting continued progress in sustainable operations, responsible business practices, and governance.
The report reflects Samsung Biologics' commitment to integrating sustainability into its business and operations while meeting the evolving expectations of clients, stakeholders, and the broader biopharmaceutical industry. To further enhance the transparency and accessibility of its disclosures, the company continued to advance its reporting framework in alignment with the European Sustainability Reporting Standards (ESRS) and published a dedicated ESG Factbook that provides a consolidated view of key sustainability metrics and performance data.
During the reporting period, Samsung Biologics accelerated its environmental performance through renewable energy transition, greenhouse gas emissions management, and enhanced carbon reporting. The company's renewable energy transition rate under its RE100 roadmap increased to 39.8%, while Scope 3 greenhouse gas emissions reporting coverage expanded from 56.3% to 63.7%, providing greater visibility across its value chain. Samsung Biologics also achieved third-party validation of its product carbon footprint (PCF) methodology, supporting clearer communication in sustainability reporting. In addition, the company received an 'A' rating in Water Security from the Carbon Disclosure Project (CDP), reflecting its ongoing focus on environmental stewardship and resource management.
On the social front, Samsung Biologics focused on talent cultivation and broader value chain engagement. The company operated career development programs in partnership with leading educational institutions to help cultivate future biotechnology talent, while also advancing professional growth and leadership opportunities for women in its workforce. The company also expanded supplier sustainability assessments and engagement programs, with participation reaching 57.3%, helping strengthen responsible sourcing practices and supply chain resilience.
The company further enhanced its governance framework by strengthening ethical risk management and advancing oversight practices. Through a more diversified evaluation approach, Samsung Biologics reinforced the objectivity, credibility, and independence of governance oversight, supporting effective decision-making and long-term value creation.
Beyond its own operations, Samsung Biologics engaged with stakeholders across the healthcare ecosystem to support industry-wide sustainability goals. As a champion of the Sustainable Markets Initiative (SMI) Health Systems Task Force, the company actively participated in collaborative efforts aimed at advancing more sustainable healthcare value chains and supporting the industry's transition toward a lower-carbon future.
“Sustainability is an important part of how we operate and create long-term value,” said John Rim, President and CEO of Samsung Biologics. “Through steady investments in environmental performance, robust governance, and industry-wide collaboration, we aim to contribute to the long-term resilience of the industry and the patients it serves.”
The full report is available here.
Share article
Related Content